Myasthenia Gravis Market: By Type (Ocular Myasthenia Gravis, Congenital Myasthenia Gravis, Generalized Myasthenia Gravis, Transient Myasthenia Gravis and Others), (Diagnosis and Treatment), End User (Hospitals and Clinics, Diagnostic Centers and Academic and Research Organizations) and By Region-Global Forecast Till 2027
Myasthenia Gravis Market Highlights
The global myasthenia gravis disease market is expected to exhibit a strong 7.5% CAGR over the forecast period from 2017 to 2023, according to the latest research report from Market Research Future (MRFR).
Competitive Analysis:
Leading players in the global myasthenia gravis disease market include Fresenius Kabi, GSK plc, AbbVie Inc., Biogen Inc., Bristol-Myers Squibb Co., F. Hoffman-La Roche Ltd., Cipla, RPG Life Sciences, Teva Pharmaceutical Industries Ltd., Apotex Corporation, Novartis, Piramal Healthcare, Sun Pharmaceuticals Industries Ltd., and Valeant.
Research projects are likely to be crucial for the global myasthenia gravis disease market over the forecast period. In July 2019, a new case report from a man suffering from both multiple sclerosis and myasthenia gravis showed that the two diseases may share common autoimmune responses. In August 2019, a research team from Chongqing Medical University and SUNY Upstate Medical University found that gut microbes and metabolic changes could provide an accurate biomarker for myasthenia gravis disease. Such efforts are likely to remain crucial for the global myasthenia gravis disease market over the forecast period.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/7267
Segmentation:
The global myasthenia gravis disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global myasthenia gravis disease market can be segmented into imaging, blood tests, electrodiagnostic, edrophonium tests, pulmonary function tests, and others. The imaging segment is classified into X-ray, computed tomography (CT), magnetic resonance imaging (MRI), and others.
On the basis of treatment, the global myasthenia gravis disease market can be segmented into medication, surgery, autologous hematopoietic stem cell transplantation (HSCT), plasmapheresis and intravenous immunoglobulin, and others. By medication, the market is divided into acetylcholinesterase inhibitors, immunosuppressants, steroids, and others. The acetylcholinesterase inhibitors segment is further classified into atropine, neostigmine, pyridostigmine, and others. Immunosuppressant drugs are further divided into azathioprine, mycophenolate mofetil, tacrolimus, and rituximab. The steroids segment is further divided into prednisone and others. Surgery is divided into thymectomy and others.
On the basis of end user, the global myasthenia gravis disease market is segmented into hospitals, clinics, academic research institutes, and others.
Regional Analysis:
The global myasthenia gravis disease market is expected to be dominated by North America over the forecast period, with the Americas segment holding the dominant share in the market. The Americas market for myasthenia gravis disease is mainly driven by the growing awareness about the disease, as neurological diseases have been studied in detail in the region and awareness about this kind of disease is significantly high in the region. The growing demand for effective medications for neuromuscular diseases such as myasthenia gravis is likely to drive the drug development scenario in the Americas region over the forecast period, leading to steady growth of the myasthenia gravis disease market.
Europe holds the second largest share in the global myasthenia gravis disease market and is likely to remain a leading contender in the global market over the forecast period due to the growing awareness about neuromuscular conditions. Myasthenia gravis holds a significant position in the Europe market, as the disease can cause a significant burden on national healthcare systems. The increasing financial burden of myasthenia gravis disease is likely to drive the myasthenia gravis disease market in Europe over the forecast period.
Asia Pacific is likely to be a major regional market for myasthenia gravis disease over the forecast period due to the growing awareness about the disease and the increasing desire to eliminate the disease from urban populations in growing economies such as China, India, Japan, and South Korea. Increasing healthcare expenditure in the region is likely to be a major driver for the myasthenia gravis disease market over the forecast period. Rising awareness about neuromuscular diseases is likely to be a key driver for the myasthenia gravis disease market in Asia Pacific over the forecast period.
The Middle East and Africa is likely to retain a low share in the global myasthenia gravis disease market over the forecast period due to the lack of awareness about the disease in the region and the low disposable income of consumers in the region.
Browse Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/myasthenia-gravis-market-7267
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Contact:
Akash Anand
Market Research Future
+1 646 845 9312
Email: [email protected]
Overview:The latest study conducted by Market Research Future (MRFR) reveals the global myasthenia gravis (MG) is set to witness 9.61% CAGR during the assessment period (2018-2023) and surpass a valuation of USD 3,000 Mn.
In recent years, a sharp rise in MG and related incidences has been noticed.
It is understood that early diagnosis and treatment can reduce the impact of the condition to a significant extent, however outcomes may vary from case to case.
Nonetheless, high cost of treatment is currently viewed as the primary restraint for the markets Request Sample Copy:https://www.marketresearchfuture.com/sample_request/7267Segmental AnalysisThe report includes a segmental analysis of the market, which covers disease type, end-user, diagnosis and treatment and region.
Sub-segments of the diagnosis segment that are discussed in the report are electrodiagnostic testing, imaging and Lab-based test.Sub-segments of the treatment segment discussed in the report are plasmapheresis and intravenous immunoglobulin, immunosuppressive drugs, thymectomy and cholinesterase inhibitors.
By end user, the market has been segmented into academic and research organizations, diagnostic centers and hospitals and clinics.
